KEY DIAGNOSTIC TESTING MARKETS

Table of Contents

1.Overview

• 1.1 Objective
• 1.2 Content and Scope
• 1.3 Methodology
• 1.4 Executive Summary

2. Introduction

• 2.1 Basic Structure and Perspectives
• 2.2 Global Diagnostic Products Industry Status and Prognosis
• 2.3 Size, Structure, and Growth of the Industry
  • 2.3.1 Current Market Size
  • 2.3.2 Market Segments
    • 2.3.2.1 Clinical Chemistry
    • 2.3.2.2 Immunoassays
    • 2.3.2.3 Nucleic Acid Arrays
    • 2.3.2.4 Coagulation Tests
• 2.4 Trends and Forces Driving the Industry
  • 2.4.1 Global Demographics
  • 2.4.2 Healthcare Delivery and Disease Management
  • 2.4.3 Technologic Innovation
• 2.5 Alternate Site Diagnostic Testing

3. Market Analysis

• 3.1 Glucose Monitoring
  • 3.1.1 Market Size
  • 3.1.2 Competitive Landscape
• 3.2 Rapid Coagulation Testing
• 3.3 Rapid Cardiac Markers
  • 3.3.1 Troponins
  • 3.3.2 BNP Testing
• 3.4 Drugs of Abuse Screening Testing
• 3.5 Infectious Disease Testing
  • 3.5.1 Campylobacter Species
  • 3.5.2 Chlamydia Species
  • 3.5.3 Clostridium difficile
  • 3.5.4 Cryptosporidium Species
  • 3.5.5 Dengue
  • 3.5.6 Entamoeba histolytica
  • 3.5.7 Giardia Species
  • 3.5.8 Helicobacter pylori
  • 3.5.9 Hepatitis Testing
    • 3.5.9.1 Overview
    • 3.5.9.2 Immunological Testing
      • 3.5.9.2.1 Hepatitis A (HAV)
      • 3.5.9.2.2 Hepatitis B (HBV)
      • 3.5.9.2.3 Hepatitis C (HCV)
      • 3.5.9.2.4 Hepatitis D (HDV)
      • 3.5.9.2.5 Hepatitis E
  • 3.5.10 HIV
  • 3.5.11 Rapid Influenza Testing
  • 3.5.12 Mononucleosis
  • 3.5.13 Rubella
  • 3.5.14 Salmonella Species
  • 3.5.15 Shiga-Toxin-Producing Escherichia coli
  • 3.5.16 Staphylococcus Species
  • 3.5.17 Streptococcus Species
  • 3.5.18 TB and Lyme Disease
• 3.6 Cholesterol Testing
• 3.7 Tumor Markers
  • 3.7.1 Market Description
  • 3.7.2 Clinical Diagnostic Serum Based Markers
  • 3.7.3 PSA Testing
  • 3.7.4 Other Markers

4. Business Trends

• 4.1 Industry Consolidation
• 4.2 Breath of Product Offering & Pricing
• 4.3 Government Regulation of Medical Devices
• 4.4 Clinical Laboratory Improvement Act (CLIA)
• 4.5 Reimbursement Issues

5. Patient Management Trends

• 5.1 Satellite Facilities
• 5.2 Point of Care Testing
• 5.3 In-Office Testing
• 5.4 Home Care Analysis
• 5.5 Non-traditional Methods for Sample Collecting

6. Technology Trends

• 6.1 Sensor Systems for Diagnostic Applications
• 6.2 Glucose Measurements
• 6.3 Cholesterol Testing
• 6.4 The New Workflow Paradigm
  • 6.4.1 Consolidated Workstations and Modularity
  • 6.4.2 Laboratory Automation & Robotics
  • 6.4.3 Laboratory Information Systems
• 6.5 Biosensor Technology
• 6.6 Protein Sequencing
• 6.7 DNA Sequencing
• 6.8 The Human Genome Project
• 6.9 Liquid Phase Chromatography
• 6.10 Polymerase Chain Reaction (PCR)
• 6.11 Capillary Electrophoresis
• 6.12 Proteomics

7. Alternate Site Testing: Hospital Issues

• 7.1 Moderators of Growth for Point of Care Testing
  • 7.1.1 Quality Assurance Issues
  • 7.1.2 Political Control
  • 7.1.3 Regulatory Requirements
  • 7.1.4 Finance
• 7.2 Attitudes of Critical Care Nurses and Physicians
• 7.3 Personnel for Point of Care Testing
• 7.4 Data Management Issues
  • 7.4.1 Wireless LANS
  • 7.4.2 Hospital Costs of Information Management
  • 7.4.3 Other Information Processing Capabilities
• 7.5 Patient Focused Outcome Measurements
• 7.6 Patient Care and Reimbursement
• 7.7 Decentralization Issues
• 7.8 Clinical Outcomes
• 7.9 Focused Testing
• 7.10 Satellite Facilities
• 7.11 Point of Care Testing

8. Strategic Assessments

• 8.1 Glucose Monitoring
• 8.2 Tumor Markers
• 8.3 Cardiac Markers
• 8.4 Infectious Disease Testing
• 8.5 Coagulation Testing
• 8.6 Drugs of Abuse Testing/Therapeutic Drug Monitoring

9. Market Trends & Forecasts

10. Corporate Directories